Cost-Utility Analysis of Oxybutynin vs. OnabotulinumtoxinA (Botox) in the Treatment of Overactive Bladder Syndrome

Habiba Shabir, Sana Hashemi, Moussa Al-Rufayie, Tayo Adelowo, Umar Riaz, Umayair Ullah, Benyamin Alam, Mehreen Anwar and Laure de Preux
Additional contact information
Habiba Shabir: Department of Management and Entrepreneurship, Business School, Imperial College London, London SW7 2BX, UK
Sana Hashemi: Department of Management and Entrepreneurship, Business School, Imperial College London, London SW7 2BX, UK
Moussa Al-Rufayie: Department of Management and Entrepreneurship, Business School, Imperial College London, London SW7 2BX, UK
Tayo Adelowo: Department of Management and Entrepreneurship, Business School, Imperial College London, London SW7 2BX, UK
Umar Riaz: Department of Management and Entrepreneurship, Business School, Imperial College London, London SW7 2BX, UK
Umayair Ullah: Department of Management and Entrepreneurship, Business School, Imperial College London, London SW7 2BX, UK
Benyamin Alam: Faculty of Biology, Medicine and Health, University of Manchester, Manchester M13 9PL, UK
Mehreen Anwar: Department of Management and Entrepreneurship, Business School, Imperial College London, London SW7 2BX, UK

IJERPH, 2021, vol. 18, issue 16, 1-15

Abstract: Background: The UK National Health Service (NHS) propose the use of oxybutynin prior to onabotulinumtoxinA (Botox) in the management of overactive bladder syndrome (OAB). Oxybutynin is costly and associated with poor adherence, which may not occur with Botox. We conducted a cost-utility analysis (CUA) to compare the medications. Methods: we compared the two treatments in quality-adjusted life years (QALYS), through the NHS’s perspective. Costs were obtained from UK-based sources and were discounted. Total costs were determined by adding the treatment cost and management cost for complications on each branch. A 12-month time frame was used to model the data into a decision tree. Results: Our results found that using Botox first-line had greater cost utility than oxybutynin. The health net benefit calculation showed an increase in 0.22 QALYs when Botox was used first-line. Botox also had greater cost-effectiveness, with the exception of pediatric patients with an ICER of £42,272.14, which is above the NICE threshold of £30,000. Conclusion: Botox was found to be more cost-effective than antimuscarinics in the management of OAB in adults, however less cost-effective in younger patients. This predicates the need for further research to ascertain the age at which Botox becomes cost-effective in the management of OAB.

Keywords: economic evaluation; cost-utility; oxybutynin; onobotulinumtoxinA; overactive bladder syndrome (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2021
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/18/16/8743/pdf (application/pdf)
https://www.mdpi.com/1660-4601/18/16/8743/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:18:y:2021:i:16:p:8743-:d:617322

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().